Puma Biotechnology, Inc. (PBYI)
| Market Cap | 141.89M |
| Revenue (ttm) | 230.47M |
| Net Income (ttm) | 30.28M |
| Shares Out | 49.61M |
| EPS (ttm) | 0.62 |
| PE Ratio | 4.61 |
| Forward PE | 7.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 234,096 |
| Open | 2.820 |
| Previous Close | 2.860 |
| Day's Range | 2.760 - 2.850 |
| 52-Week Range | 2.230 - 5.340 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+144.76%) |
| Earnings Date | May 1, 2025 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast can... [Read more]
Financial Performance
In 2024, Puma Biotechnology's revenue was $230.47 million, a decrease of -2.19% compared to the previous year's $235.64 million. Earnings were $30.28 million, an increase of 40.23%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma SE: Undervalued With Tailwinds Ahead
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performanc...
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
PUMA SE: This Is The Right Time To Buy
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenu...
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Presid...
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.
Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET.
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stabl...
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated a clinical trial of alisertib with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Cha...
Puma Biotechnology Reports Third Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Nov. 7, Puma Biotechnology issued its earnings results for 3Q-2024 and hosted a conference call to discuss the details.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 3Q-2024 results after markets close on Nov. 7 and host a conference call to discuss results at 1:30 pm PT.
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company overview on Sept. 9 at H.C. Wainwright's 26th Annual Global Inv. Conf.
Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Off...
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its second quarter financial results and hosted a conference call on August 1, 2024.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
Puma Biotechnology to Join Russell 3000 Index
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.
Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Execut...
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will report its financial results for 1Q-2024 after the close and host a conference call at 1:30 p.m. PT on May 2.